Volasertib

Drug Profile

Volasertib

Alternative Names: BI-6727

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Amides; Antineoplastics; Piperazines; Pteridines; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer
  • Phase I Chronic myelomonocytic leukaemia; Leukaemia; Solid tumours
  • No development reported Urogenital cancer

Most Recent Events

  • 10 Jan 2017 Boehringer Ingelheim terminates phase I trial for Myelodysplastic syndromes or Chronic myelomonocytic leukaemia in Germany and France (IV) (NCT01957644)
  • 19 Dec 2016 Boehringer Ingelheim terminates a phase I trial in Myelodysplastic syndromes (Second-line therapy or greater, Monotherapy) in Spain, Singapore, France and Japan (IV) (NCT02721875)
  • 02 Dec 2016 University of Ulm terminates a phase III trial in Acute myeloid leukaemia (First-line therapy, Combination therapy) and Myelodysplastic syndromes (Combination therapy, First-line therapy) in Germany due to manufacturing problems (NCT02198482)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top